CurrentUnitedHealthcarePolicy N/A

Prior authorization form for biologic therapy for Rheumatoid Arthritis

This document is a beneficiary/provider prior authorization form used to request coverage for a biologic immunomodulator for rheumatoid arthritis and documents clinical screening, prior therapy trials, and safety considerations. It affects prescribers requesting coverage and UnitedHealthcare eligibility reviewers.

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization form for biologic therapy for Rheumatoid Arthritis

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionComplete the RA-specific questionnaire including diagnosis confirmation, prior TNF blocker trial or contraindication, safety screenings, therapy duration selection, and prescriber attestation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

10+clinical screening and prior-therapy questions on form

up to 365dselectable therapy duration options

signatureattestation required

Coverage Criteria and Clinical Requirements

Initial Authorization Criteria (form-based)

Covered when ALL of the following are met as attested on the form

Diagnosis: Beneficiary has a diagnosis of Rheumatoid Arthritis (attested Yes)

Form item 1 requires Yes

Prior biologic exposure: Beneficiary is not currently on another injectable biologic immunomodulator or prior TNF blocker trial documented or contraindication/intolerance documented

Form items 2,8,9,10 capture current biologic status and prior Enbrel/Humira trial or reason cannot try

Safety screening: Beneficiary has been screened for latent tuberculosis and tested for Hepatitis B (SAg and Core Ab), will not receive live vaccines during therapy, and individual risks for malignancy/MACE and thrombosis have been considered (attested Yes)

Form items 3-7 capture these safety checks

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization form for biologic therapy for Rheumatoid Arthritis

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Requirements, Prior Authorization, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for RA biologic therapy. Complete the RA-specific prior authorization questionnaire and submit with the request. The form must confirm the RA diagnosis and provide clinical justification for biologic therapy when applicable.

Complete the RA-specific questionnaire section titled 'Request for Rheumatoid Arthritis'.
Confirm primary diagnosis: Rheumatoid Arthritis (Yes/No).
Provide prescriber signature and date (mandatory).
Include prescriber NPI and requester contact information.

Step Therapy

Step Therapy Expectation

Step therapy expectations apply. The form asks whether the beneficiary had a trial and failure of Enbrel (etanercept) or Humira (adalimumab) or documents a clinical reason they cannot try these agents.

Document prior trial and inadequate response to at least one TNF blocker (Yes/No).
If no TNF blocker trial, provide clinical reason or contraindication preventing use of Enbrel or Humira.
Indicate explicitly whether beneficiary had trial/failure of Enbrel or Humira or has a documented clinical reason they cannot try them.

Documentation Required

Required Documentation on Form

Provide complete documentation on the prior authorization form. Missing or incomplete information may delay review or result in denial.

Beneficiary demographics: name, ID #, date of birth, gender.
Prescriber information: NPI number, requester contact name, phone and extension.
Drug details: drug name, strength, quantity per 30 days, and selected length of therapy (30–365 days or other).
Clinical responses: answers to RA-specific questions (TB screening, Hep B testing, live vaccine status, thrombosis risk, MACE/malignancy risk discussion).
Documentation of therapeutic failure/inadequate response to TNF blockers or documentation of contraindication/intolerance.
Prescriber signature and date (mandatory).

Denial Risk

Potential Denial Triggers

Requests may be denied if required clinical information or step-therapy requirements are not met or documented.

Missing confirmation of Rheumatoid Arthritis diagnosis.
No documentation of prior trial and failure of a TNF blocker or no documented contraindication/intolerance that prevents TNF blocker use.
Incomplete beneficiary or prescriber information (missing NPI, contact info, or beneficiary ID/DOB).
Absent prescriber signature or date.
Lack of required screening documentation (latent TB screening, Hep B testing) when applicable.

Clinical Background

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease for which biologic immunomodulators are commonly used when conventional therapies are insufficient. The form requires prescriber attestation that the beneficiary has RA, that individual risks (including malignancy and major adverse cardiovascular events) and thrombosis risk have been considered, and that safety screening has been completed for latent tuberculosis and Hepatitis B (SAg and Core Ab). The form also documents prior exposure or therapeutic failure with Tumor Necrosis Factor blockers (for example, Enbrel or Humira) or a clinical reason the beneficiary cannot receive them, reflecting the clinical rationale for stepwise use of TNF blockers before other biologics in many treatment pathways.

Key Definitions

Tumor Necrosis Factor Blocker (TNF blocker)

DefinitionTumor Necrosis Factor (TNF) blocker: a class of biologic agents referenced on the form as prior therapies to document trial/failure or contraindication/intolerance.

Examples cited on formEtanercept (Enbrel) and adalimumab (Humira)

Form useForm asks whether beneficiary has experienced therapeutic failure with at least one TNF blocker and whether beneficiary is unable to receive TNF blockers due to contraindication or intolerance.

Step-therapy roleForm specifically asks if beneficiary had trial and failure of Enbrel or Humira or a clinical reason they cannot try them, indicating expectation to try these agents before other biologics unless contraindicated.

Documentation implicationA documented trial/failure or documented contraindication/intolerance to TNF blockers is required on the form for prior authorization consideration.